141 related articles for article (PubMed ID: 36540923)
41. Impact factors for the outcome of the first
Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
[TBL] [Abstract][Full Text] [Related]
42. [Clinicopathological and ultrasound characteristics of extranodal extension in metastatic papillary thyroid carcinoma patients].
Mu JL; Li FX; Wei X; Xin XJ; Zhang S
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):264-267. PubMed ID: 29730912
[No Abstract] [Full Text] [Related]
43. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract][Full Text] [Related]
44. Impact of age on survival in radioiodine refractory differentiated thyroid cancer patients.
Saïe C; Wassermann J; Mathy E; Chereau N; Leenhardt L; Tezenas du Montcel S; Buffet C
Eur J Endocrinol; 2021 May; 184(5):667-676. PubMed ID: 33667193
[TBL] [Abstract][Full Text] [Related]
45. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
[TBL] [Abstract][Full Text] [Related]
46. Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer.
Momesso DP; Vaisman F; Caminha LS; Pessoa CH; Corbo R; Vaisman M
J Endocrinol Invest; 2014 Jan; 37(1):57-64. PubMed ID: 24464451
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes.
Xu S; Huang H; Qian J; Liu Y; Huang Y; Wang X; Liu S; Xu Z; Liu J
JAMA Netw Open; 2021 Jul; 4(7):e2118526. PubMed ID: 34313737
[TBL] [Abstract][Full Text] [Related]
48. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
[TBL] [Abstract][Full Text] [Related]
49. Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up.
Qiu ZL; Shen CT; Sun ZK; Song HJ; Xi C; Zhang GQ; Wang Y; Luo QY
Front Endocrinol (Lausanne); 2020; 11():588024. PubMed ID: 33716950
[TBL] [Abstract][Full Text] [Related]
50. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
51. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
[TBL] [Abstract][Full Text] [Related]
52. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
[TBL] [Abstract][Full Text] [Related]
53. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
54. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.
Zhang XY; Sun JW; Qiu ZL; Wang Y; Chen XY; Zhao JH; Luo QY
Endocrine; 2019 Nov; 66(2):254-265. PubMed ID: 31317522
[TBL] [Abstract][Full Text] [Related]
55. Lymph node metastases >5 and metastatic lymph node ratio >0.30 of differentiated thyroid cancer predict response to radioactive iodine.
Yun C; Xiao J; Cao J; Shao C; Wang L; Zhang W; Jia H
Cancer Med; 2021 Nov; 10(21):7610-7619. PubMed ID: 34622559
[TBL] [Abstract][Full Text] [Related]
56. Papillary thyroid cancer: factors involved in restaging N1 disease after total thyroidectomy and radioactive iodine treatment.
Guy A; Hirsch D; Shohat T; Bachar G; Tirosh A; Robenshtok E; Shimon I; Benbassat CA
J Clin Endocrinol Metab; 2014 Nov; 99(11):4167-73. PubMed ID: 25157544
[TBL] [Abstract][Full Text] [Related]
57. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
58. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
59. Breach of the thyroid capsule and lymph node capsule in node-positive papillary and medullary thyroid cancer: Different biology.
Machens A; Dralle H
Eur J Surg Oncol; 2015 Jun; 41(6):766-72. PubMed ID: 25468749
[TBL] [Abstract][Full Text] [Related]
60. Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer.
Mu Z; Zhang X; Liang D; Fang J; Chen G; Guo W; Sun D; Sun Y; Kai Z; Huang L; Liang J; Lin Y
Chin J Cancer Res; 2024 Feb; 36(1):25-35. PubMed ID: 38455372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
